By Mill Chart
Last update: Apr 10, 2024
In this article we will dive into ALKERMES PLC (NASDAQ:ALKS) as a possible candidate for growth investing. Investors should always do their own research, but we noticed ALKERMES PLC showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.
ChartMill assigns a Fundamental Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple fundamental indicators and properties.
Overall ALKS gets a fundamental rating of 6 out of 10. We evaluated ALKS against 589 industry peers in the Biotechnology industry. ALKS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ALKS scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes ALKS very considerable for value investing!
Check the latest full fundamental report of ALKS for a complete fundamental analysis.
More growth stocks can be found in our Lois Navellier screen.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
ALKERMES PLC
NASDAQ:ALKS (4/29/2024, 3:30:01 PM)
After market: 24.88 0 (0%)24.88
+0.2 (+0.81%)
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors...
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.